<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Nephrology Now &#187; General Nephrology</title>
	<atom:link href="http://www.nephrologynow.com/publications/category/general-nephrology/feed" rel="self" type="application/rss+xml" />
	<link>http://www.nephrologynow.com</link>
	<description></description>
	<lastBuildDate>Tue, 20 Jul 2010 07:46:28 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<script type="text/javascript">

if (typeof Meebo == 'undefined') {

Meebo=function(){(Meebo._=Meebo._||[]).push(arguments)};
(function(q){

	var args = arguments;
	if (!document.body) { return setTimeout(function(){ args.callee.apply(this, args) }, 100); }
	var d=document, b=d.body, m=b.insertBefore(d.createElement('div'), b.firstChild); s=d.createElement('script');
	m.id='meebo'; m.style.display='none'; m.innerHTML='<iframe id="meebo-iframe"></iframe>';
	s.src='http'+(q.https?'s':'')+'://'+(q.stage?'stage-':'')+'cim.meebo.com/cim/cim.php?network='+q.network;
	b.insertBefore(s, b.firstChild);

})({network:'nephrologynow_bi16va'});	}</script>	<item>
		<title>Update in Nephrology</title>
		<link>http://www.nephrologynow.com/publications/update-in-nephrology-2</link>
		<comments>http://www.nephrologynow.com/publications/update-in-nephrology-2#comments</comments>
		<pubDate>Tue, 20 Jul 2010 07:10:01 +0000</pubDate>
		<dc:creator>Nephrology Now editors</dc:creator>
				<category><![CDATA[General Nephrology]]></category>
		<category><![CDATA[Review]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com/?p=1518</guid>
		<description><![CDATA[This article highlights the findings of several key trials that were published in the field of chronic kidney disease in 2009.
Related Articles:

Stage IV Chronic Kidney Disease
Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease
Erythropoiesis-Stimulating Agents — Time for a Reevaluation


]]></description>
			<content:encoded><![CDATA[<div>This article highlights the findings of several key trials that were published in the field of chronic kidney disease in 2009.</div>
<p><strong>Related Articles:</strong>
<ul class="similar-posts">
<li><a href="http://www.nephrologynow.com/publications/stage-iv-chronic-kidney-disease" rel="bookmark" title="January 11, 2010">Stage IV Chronic Kidney Disease</a></li>
<li><a href="http://www.nephrologynow.com/publications/randomized-clinical-trial-of-long-acting-somatostatin-for-autosomal-dominant-polycystic-kidney-and-liver-disease" rel="bookmark" title="June 6, 2010">Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease</a></li>
<li><a href="http://www.nephrologynow.com/publications/erythropoiesis-stimulating-agents-%e2%80%94-time-for-a-reevaluation" rel="bookmark" title="January 11, 2010">Erythropoiesis-Stimulating Agents — Time for a Reevaluation</a></li>
</ul>
<p><!-- Similar Posts took 6.146 ms --></p>
<img style='display:none' id="post-1518-blankimage" onload="Meebo('discoverSharable', {element: ((this.parentNode.className.match('post')) ? this.parentNode : this.parentNode.parentNode) ,url:'http://www.nephrologynow.com/publications/update-in-nephrology-2',title:'Update in Nephrology',tweet:'This article highlights the findings of several key trials that were published in the field of chron',description:'This article highlights the findings of several key trials that were published in the field of chron'})"><script type='text/javascript'></script>]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/update-in-nephrology-2/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Byetta (exenatide) Associated with Risk of Renal Failure</title>
		<link>http://www.nephrologynow.com/publications/fda-byetta-exenatide-associated-with-risk-of-renal-failure</link>
		<comments>http://www.nephrologynow.com/publications/fda-byetta-exenatide-associated-with-risk-of-renal-failure#comments</comments>
		<pubDate>Sun, 22 Nov 2009 21:16:52 +0000</pubDate>
		<dc:creator>Nephrology Now editors</dc:creator>
				<category><![CDATA[Acute Renal Failure]]></category>
		<category><![CDATA[General Nephrology]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com/?p=1249</guid>
		<description><![CDATA[FDA notified healthcare professionals of revisions to the prescribing information for Byetta (exenatide) to include information on post-marketing reports of altered kidney function, including acute renal failure and insufficiency. Byetta, an incretin-mimetic, is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Related Articles:

Influence of Renal [...]]]></description>
			<content:encoded><![CDATA[<p>FDA notified healthcare professionals of revisions to the prescribing information for Byetta (exenatide) to include information on post-marketing reports of altered kidney function, including acute renal failure and insufficiency. Byetta, an incretin-mimetic, is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.<strong>Related Articles:</strong>
<ul class="similar-posts">
<li><a href="http://www.nephrologynow.com/publications/influence-of-renal-function-on-the-effects-of-early-revascularization-in-non-st-elevation-myocardial-infarction" rel="bookmark" title="September 13, 2009">Influence of Renal Function on the Effects of Early Revascularization in Non-ST-Elevation Myocardial Infarction</a></li>
<li><a href="http://www.nephrologynow.com/publications/incidence-and-predictive-factors-for-infectious-disease-after-rituximab-therapy-in-kidney-transplant-patients" rel="bookmark" title="January 11, 2010">Incidence and Predictive Factors for Infectious Disease after Rituximab Therapy in Kidney-Transplant Patients</a></li>
<li><a href="http://www.nephrologynow.com/publications/kidney-transplantation-and-hiv-does-recipient-privacy-outweigh-the-donors-right-to-information" rel="bookmark" title="June 6, 2010">Kidney Transplantation and HIV: Does Recipient Privacy Outweigh the Donor&#8217;s Right to Information?</a></li>
</ul>
<p><!-- Similar Posts took 8.004 ms --></p>
<img style='display:none' id="post-1249-blankimage" onload="Meebo('discoverSharable', {element: ((this.parentNode.className.match('post')) ? this.parentNode : this.parentNode.parentNode) ,url:'http://www.nephrologynow.com/publications/fda-byetta-exenatide-associated-with-risk-of-renal-failure',title:'FDA Byetta (exenatide) Associated with Risk of Renal Failure',tweet:'FDA notified healthcare professionals of revisions to the prescribing information for Byetta (exenat',description:'FDA notified healthcare professionals of revisions to the prescribing information for Byetta (exenat'})"><script type='text/javascript'></script>]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/fda-byetta-exenatide-associated-with-risk-of-renal-failure/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Serum free light chain assessment in monoclonal gammopathy and kidney disease.</title>
		<link>http://www.nephrologynow.com/publications/serum-free-light-chain-assessment-in-monoclonal-gammopathy-and-kidney-disease</link>
		<comments>http://www.nephrologynow.com/publications/serum-free-light-chain-assessment-in-monoclonal-gammopathy-and-kidney-disease#comments</comments>
		<pubDate>Sun, 22 Nov 2009 21:00:30 +0000</pubDate>
		<dc:creator>Nephrology Now editors</dc:creator>
				<category><![CDATA[General Nephrology]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com/?p=1239</guid>
		<description><![CDATA[This review examines the evidence associated with the use of the free light chain assay.Related Articles:

Stage IV Chronic Kidney Disease
The importance of residual kidney function for patients on dialysis: a critical review.
Staphylococcus aureus Infections in Hemodialysis: What a Nephrologist Should Know


]]></description>
			<content:encoded><![CDATA[<p>This review examines the evidence associated with the use of the free light chain assay.<strong>Related Articles:</strong>
<ul class="similar-posts">
<li><a href="http://www.nephrologynow.com/publications/stage-iv-chronic-kidney-disease" rel="bookmark" title="January 11, 2010">Stage IV Chronic Kidney Disease</a></li>
<li><a href="http://www.nephrologynow.com/publications/the-importance-of-residual-kidney-function-for-patients-on-dialysis-a-critical-review" rel="bookmark" title="June 9, 2009">The importance of residual kidney function for patients on dialysis: a critical review.</a></li>
<li><a href="http://www.nephrologynow.com/publications/staphylococcus-aureus-infections-in-hemodialysis-what-a-nephrologist-should-know" rel="bookmark" title="August 20, 2009">Staphylococcus aureus Infections in Hemodialysis: What a Nephrologist Should Know</a></li>
</ul>
<p><!-- Similar Posts took 4.055 ms --></p>
<img style='display:none' id="post-1239-blankimage" onload="Meebo('discoverSharable', {element: ((this.parentNode.className.match('post')) ? this.parentNode : this.parentNode.parentNode) ,url:'http://www.nephrologynow.com/publications/serum-free-light-chain-assessment-in-monoclonal-gammopathy-and-kidney-disease',title:'Serum free light chain assessment in monoclonal gammopathy and kidney disease.',tweet:'This review examines the evidence associated with the use of the free light chain assay.Related Arti',description:'This review examines the evidence associated with the use of the free light chain assay.Related Arti'})"><script type='text/javascript'></script>]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/serum-free-light-chain-assessment-in-monoclonal-gammopathy-and-kidney-disease/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Alterations in Renal and Urinary Tract Function</title>
		<link>http://www.nephrologynow.com/publications/alterations-in-renal-and-urinary-tract-function</link>
		<comments>http://www.nephrologynow.com/publications/alterations-in-renal-and-urinary-tract-function#comments</comments>
		<pubDate>Mon, 14 Sep 2009 04:57:06 +0000</pubDate>
		<dc:creator>Nephrology Now editors</dc:creator>
				<category><![CDATA[Educational Resource]]></category>
		<category><![CDATA[General Nephrology]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com/?p=1128</guid>
		<description><![CDATA[Free full text access to the Harrison&#8217;s chapter &#8220;Alterations in Renal and Urinary Tract Function&#8221;.Related Articles:

Staphylococcus aureus Infections in Hemodialysis: What a Nephrologist Should Know
Carotid Endarterectomy Benefits Patients with CKD and Symptomatic High-Grade Stenosis
Kidneys from Donors after Cardiac Death Provide Survival Benefit


]]></description>
			<content:encoded><![CDATA[<p>Free full text access to the Harrison&#8217;s chapter &#8220;Alterations in Renal and Urinary Tract Function&#8221;.<strong>Related Articles:</strong>
<ul class="similar-posts">
<li><a href="http://www.nephrologynow.com/publications/staphylococcus-aureus-infections-in-hemodialysis-what-a-nephrologist-should-know" rel="bookmark" title="August 20, 2009">Staphylococcus aureus Infections in Hemodialysis: What a Nephrologist Should Know</a></li>
<li><a href="http://www.nephrologynow.com/publications/carotid-endarterectomy-benefits-patients-with-ckd-and-symptomatic-high-grade-stenosis" rel="bookmark" title="January 11, 2010">Carotid Endarterectomy Benefits Patients with CKD and Symptomatic High-Grade Stenosis</a></li>
<li><a href="http://www.nephrologynow.com/publications/kidneys-from-donors-after-cardiac-death-provide-survival-benefit" rel="bookmark" title="July 20, 2010">Kidneys from Donors after Cardiac Death Provide Survival Benefit</a></li>
</ul>
<p><!-- Similar Posts took 3.804 ms --></p>
<img style='display:none' id="post-1128-blankimage" onload="Meebo('discoverSharable', {element: ((this.parentNode.className.match('post')) ? this.parentNode : this.parentNode.parentNode) ,url:'http://www.nephrologynow.com/publications/alterations-in-renal-and-urinary-tract-function',title:'Alterations in Renal and Urinary Tract Function',tweet:'Free full text access to the Harrison&#8217;s chapter &#8220;Alterations in Renal and Urinary Tract ',description:'Free full text access to the Harrison&#8217;s chapter &#8220;Alterations in Renal and Urinary Tract '})"><script type='text/javascript'></script>]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/alterations-in-renal-and-urinary-tract-function/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Lithium and chronic kidney disease</title>
		<link>http://www.nephrologynow.com/publications/lithium-and-chronic-kidney-disease</link>
		<comments>http://www.nephrologynow.com/publications/lithium-and-chronic-kidney-disease#comments</comments>
		<pubDate>Fri, 21 Aug 2009 06:49:31 +0000</pubDate>
		<dc:creator>Nephrology Now editors</dc:creator>
				<category><![CDATA[General Nephrology]]></category>
		<category><![CDATA[Review]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com/?p=1079</guid>
		<description><![CDATA[This review discusses the renal impact of lithium usage and offers guidance on monitoring, drug interactions, and when to consider discontinuation.Related Articles:

AURORA: Is There a Role for Statin Therapy in Dialysis Patients
The importance of residual kidney function for patients on dialysis: a critical review.
Erythropoiesis-Stimulating Agents — Time for a Reevaluation


]]></description>
			<content:encoded><![CDATA[<p>This review discusses the renal impact of lithium usage and offers guidance on monitoring, drug interactions, and when to consider discontinuation.<strong>Related Articles:</strong>
<ul class="similar-posts">
<li><a href="http://www.nephrologynow.com/publications/aurora-is-there-a-role-for-statin-therapy-in-dialysis-patients" rel="bookmark" title="February 12, 2010">AURORA: Is There a Role for Statin Therapy in Dialysis Patients</a></li>
<li><a href="http://www.nephrologynow.com/publications/the-importance-of-residual-kidney-function-for-patients-on-dialysis-a-critical-review" rel="bookmark" title="June 9, 2009">The importance of residual kidney function for patients on dialysis: a critical review.</a></li>
<li><a href="http://www.nephrologynow.com/publications/erythropoiesis-stimulating-agents-%e2%80%94-time-for-a-reevaluation" rel="bookmark" title="January 11, 2010">Erythropoiesis-Stimulating Agents — Time for a Reevaluation</a></li>
</ul>
<p><!-- Similar Posts took 5.813 ms --></p>
<img style='display:none' id="post-1079-blankimage" onload="Meebo('discoverSharable', {element: ((this.parentNode.className.match('post')) ? this.parentNode : this.parentNode.parentNode) ,url:'http://www.nephrologynow.com/publications/lithium-and-chronic-kidney-disease',title:'Lithium and chronic kidney disease',tweet:'This review discusses the renal impact of lithium usage and offers guidance on monitoring, drug inte',description:'This review discusses the renal impact of lithium usage and offers guidance on monitoring, drug inte'})"><script type='text/javascript'></script>]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/lithium-and-chronic-kidney-disease/feed</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
		<item>
		<title>Agalsidase Alfa and Kidney Dysfunction in Fabry Disease</title>
		<link>http://www.nephrologynow.com/publications/agalsidase-alfa-and-kidney-dysfunction-in-fabry-disease</link>
		<comments>http://www.nephrologynow.com/publications/agalsidase-alfa-and-kidney-dysfunction-in-fabry-disease#comments</comments>
		<pubDate>Fri, 01 May 2009 21:18:54 +0000</pubDate>
		<dc:creator>Nephrology Now editors</dc:creator>
				<category><![CDATA[General Nephrology]]></category>
		<category><![CDATA[Review]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/?p=797</guid>
		<description><![CDATA[Related Articles:

Agalsidase-Beta Therapy for Advanced Fabry Disease: A Randomized Trial.
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease.


]]></description>
			<content:encoded><![CDATA[Related Articles:

Agalsidase-Beta Therapy for Advanced Fabry Disease: A Randomized Trial.
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease.


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/agalsidase-alfa-and-kidney-dysfunction-in-fabry-disease/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Supramaximal Dose of Candesartan in Proteinuric Renal Disease.</title>
		<link>http://www.nephrologynow.com/publications/supramaximal-dose-of-candesartan-in-proteinuric-renal-disease</link>
		<comments>http://www.nephrologynow.com/publications/supramaximal-dose-of-candesartan-in-proteinuric-renal-disease#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[General Nephrology]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/supramaximal-dose-of-candesartan-in-proteinuric-renal-disease</guid>
		<description><![CDATA[Related Articles:

Urinary Albumin Excretion and the Risk of Graft Loss and Death in Proteinuric and Non-proteinuric Renal Transplant Recipients.
Randomized Trial of Single-Dose Versus Divided-Dose Rabbit Anti-Thymocyte Globulin Induction in Renal Transplantation: An Interim Report.
Aspirin Dose for the Prevention of Cardiovascular Disease A Systematic Review.


]]></description>
			<content:encoded><![CDATA[Related Articles:

Urinary Albumin Excretion and the Risk of Graft Loss and Death in Proteinuric and Non-proteinuric Renal Transplant Recipients.
Randomized Trial of Single-Dose Versus Divided-Dose Rabbit Anti-Thymocyte Globulin Induction in Renal Transplantation: An Interim Report.
Aspirin Dose for the Prevention of Cardiovascular Disease A Systematic Review.


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/supramaximal-dose-of-candesartan-in-proteinuric-renal-disease/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Hormonal therapies can preserve fertility in patients receiving cyclophosphamide.</title>
		<link>http://www.nephrologynow.com/publications/hormonal-therapies-can-preserve-fertility-in-patients-receiving-cyclophosphamide</link>
		<comments>http://www.nephrologynow.com/publications/hormonal-therapies-can-preserve-fertility-in-patients-receiving-cyclophosphamide#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[General Nephrology]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/hormonal-therapies-can-preserve-fertility-in-patients-receiving-cyclophosphamide</guid>
		<description><![CDATA[Related Articles:

Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide.
Can DXA Predict Fractures in Renal Transplant Patients?
Can Preemptive Cytomegalovirus Monitoring Be As Effective As Universal Prophylaxis When Implemented As the Standard of Care in Patients at Moderate Risk?


]]></description>
			<content:encoded><![CDATA[Related Articles:

Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide.
Can DXA Predict Fractures in Renal Transplant Patients?
Can Preemptive Cytomegalovirus Monitoring Be As Effective As Universal Prophylaxis When Implemented As the Standard of Care in Patients at Moderate Risk?


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/hormonal-therapies-can-preserve-fertility-in-patients-receiving-cyclophosphamide/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>American Journal of Kidney Diseases Quiz Page April 2009</title>
		<link>http://www.nephrologynow.com/publications/american-journal-of-kidney-diseases-quiz-page-april-2009</link>
		<comments>http://www.nephrologynow.com/publications/american-journal-of-kidney-diseases-quiz-page-april-2009#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[General Nephrology]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/american-journal-of-kidney-diseases-quiz-page-april-2009</guid>
		<description><![CDATA[Related Articles:

American Journal of Kidney Diseases Quiz Page April 2008
American Journal of Kidney Disease Quiz Page April 2007
American Journal of Kidney Diseases Quiz Page October 2007


]]></description>
			<content:encoded><![CDATA[Related Articles:

American Journal of Kidney Diseases Quiz Page April 2008
American Journal of Kidney Disease Quiz Page April 2007
American Journal of Kidney Diseases Quiz Page October 2007


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/american-journal-of-kidney-diseases-quiz-page-april-2009/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Prevention and treatment of renal disease in Henoch-Schönlein purpura: a systematic review.</title>
		<link>http://www.nephrologynow.com/publications/prevention-and-treatment-of-renal-disease-in-henoch-schonlein-purpura-a-systematic-review</link>
		<comments>http://www.nephrologynow.com/publications/prevention-and-treatment-of-renal-disease-in-henoch-schonlein-purpura-a-systematic-review#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[General Nephrology]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/prevention-and-treatment-of-renal-disease-in-henoch-schonlein-purpura-a-systematic-review</guid>
		<description><![CDATA[Related Articles:

Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review.
Aspirin Dose for the Prevention of Cardiovascular Disease A Systematic Review.
Sodium Bicarbonate for the Prevention of Contrast Induced-Acute Kidney Injury: A Systematic Review and Meta-analysis


]]></description>
			<content:encoded><![CDATA[Related Articles:

Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review.
Aspirin Dose for the Prevention of Cardiovascular Disease A Systematic Review.
Sodium Bicarbonate for the Prevention of Contrast Induced-Acute Kidney Injury: A Systematic Review and Meta-analysis


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/prevention-and-treatment-of-renal-disease-in-henoch-schonlein-purpura-a-systematic-review/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dermatologic conditions seen in end-stage renal disease.</title>
		<link>http://www.nephrologynow.com/publications/dermatologic-conditions-seen-in-end-stage-renal-disease</link>
		<comments>http://www.nephrologynow.com/publications/dermatologic-conditions-seen-in-end-stage-renal-disease#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[General Nephrology]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/dermatologic-conditions-seen-in-end-stage-renal-disease</guid>
		<description><![CDATA[Related Articles:

CKD stage-to-stage progression in native and transplant kidney disease.
Preventive health care in chronic kidney disease and end-stage renal disease.
Effect of Homocysteine Lowering on Mortality and Vascular Disease in Advanced Chronic Kidney Disease and End-stage Renal Disease: A Randomized Controlled Trial.


]]></description>
			<content:encoded><![CDATA[Related Articles:

CKD stage-to-stage progression in native and transplant kidney disease.
Preventive health care in chronic kidney disease and end-stage renal disease.
Effect of Homocysteine Lowering on Mortality and Vascular Disease in Advanced Chronic Kidney Disease and End-stage Renal Disease: A Randomized Controlled Trial.


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/dermatologic-conditions-seen-in-end-stage-renal-disease/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Skin problems in chronic kidney disease.</title>
		<link>http://www.nephrologynow.com/publications/skin-problems-in-chronic-kidney-disease</link>
		<comments>http://www.nephrologynow.com/publications/skin-problems-in-chronic-kidney-disease#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[General Nephrology]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/skin-problems-in-chronic-kidney-disease</guid>
		<description><![CDATA[Related Articles:

Non-melanoma skin cancer incidence and risk factors after kidney transplantation: a Canadian experience.
Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease.
Interventions for bone disease in children with chronic kidney disease.


]]></description>
			<content:encoded><![CDATA[Related Articles:

Non-melanoma skin cancer incidence and risk factors after kidney transplantation: a Canadian experience.
Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease.
Interventions for bone disease in children with chronic kidney disease.


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/skin-problems-in-chronic-kidney-disease/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Neonatal Acidosis With Nephrocalcinosis: A Clinical Approach.</title>
		<link>http://www.nephrologynow.com/publications/neonatal-acidosis-with-nephrocalcinosis-a-clinical-approach</link>
		<comments>http://www.nephrologynow.com/publications/neonatal-acidosis-with-nephrocalcinosis-a-clinical-approach#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[General Nephrology]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/neonatal-acidosis-with-nephrocalcinosis-a-clinical-approach</guid>
		<description><![CDATA[Related Articles:

Salivary phosphorus binding: a novel approach to control hyperphosphatemia.
A patient-focused approach to thrombolytic use in the management of catheter malfunction.
Posttransplant Acidosis and Associated Disorders of Mineral Metabolism in Patients With a Renal Graft.


]]></description>
			<content:encoded><![CDATA[Related Articles:

Salivary phosphorus binding: a novel approach to control hyperphosphatemia.
A patient-focused approach to thrombolytic use in the management of catheter malfunction.
Posttransplant Acidosis and Associated Disorders of Mineral Metabolism in Patients With a Renal Graft.


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/neonatal-acidosis-with-nephrocalcinosis-a-clinical-approach/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Acute allergic interstitial nephritis after use of pantoprazole.</title>
		<link>http://www.nephrologynow.com/publications/acute-allergic-interstitial-nephritis-after-use-of-pantoprazole</link>
		<comments>http://www.nephrologynow.com/publications/acute-allergic-interstitial-nephritis-after-use-of-pantoprazole#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[General Nephrology]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/acute-allergic-interstitial-nephritis-after-use-of-pantoprazole</guid>
		<description><![CDATA[Related Articles:

Candidemia-Induced Acute Interstitial Nephritis.
A case of cocaine-induced acute interstitial nephritis.
Four cases of nafcillin-associated acute interstitial nephritis in one institution


]]></description>
			<content:encoded><![CDATA[Related Articles:

Candidemia-Induced Acute Interstitial Nephritis.
A case of cocaine-induced acute interstitial nephritis.
Four cases of nafcillin-associated acute interstitial nephritis in one institution


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/acute-allergic-interstitial-nephritis-after-use-of-pantoprazole/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Kidney involvement in multicentric castleman disease.</title>
		<link>http://www.nephrologynow.com/publications/kidney-involvement-in-multicentric-castleman-disease</link>
		<comments>http://www.nephrologynow.com/publications/kidney-involvement-in-multicentric-castleman-disease#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[General Nephrology]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/kidney-involvement-in-multicentric-castleman-disease</guid>
		<description><![CDATA[Related Articles:

Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement.
Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease.
Effect of Homocysteine Lowering on Mortality and Vascular Disease in Advanced Chronic Kidney Disease and End-stage Renal Disease: A [...]]]></description>
			<content:encoded><![CDATA[Related Articles:

Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement.
Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease.
Effect of Homocysteine Lowering on Mortality and Vascular Disease in Advanced Chronic Kidney Disease and End-stage Renal Disease: A [...]]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/kidney-involvement-in-multicentric-castleman-disease/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>American Journal of Kidney Diseases Quiz Page March 2009</title>
		<link>http://www.nephrologynow.com/publications/american-journal-of-kidney-diseases-quiz-page-march-2009</link>
		<comments>http://www.nephrologynow.com/publications/american-journal-of-kidney-diseases-quiz-page-march-2009#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[General Nephrology]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/american-journal-of-kidney-diseases-quiz-page-march-2009</guid>
		<description><![CDATA[Related Articles:

American Journal of Kidney Diseases Quiz Page March 2008
American Journal of Kidney Diseases Quiz Page October 2007
American Journal of Kidney Diseases Quiz Page September 2007


]]></description>
			<content:encoded><![CDATA[Related Articles:

American Journal of Kidney Diseases Quiz Page March 2008
American Journal of Kidney Diseases Quiz Page October 2007
American Journal of Kidney Diseases Quiz Page September 2007


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/american-journal-of-kidney-diseases-quiz-page-march-2009/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura .</title>
		<link>http://www.nephrologynow.com/publications/interventions-for-haemolytic-uraemic-syndrome-and-thrombotic-thrombocytopenic-purpura</link>
		<comments>http://www.nephrologynow.com/publications/interventions-for-haemolytic-uraemic-syndrome-and-thrombotic-thrombocytopenic-purpura#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[General Nephrology]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/interventions-for-haemolytic-uraemic-syndrome-and-thrombotic-thrombocytopenic-purpura</guid>
		<description><![CDATA[Related Articles:

Thrombotic microangiopathy and renal failure exacerbated by epsilon-aminocaproic acid.
Association between high ultrafiltration rates and mortality in uraemic patients on regular haemodialysis. A 5-year prospective observational multicentre study.
Prevention and treatment of renal disease in Henoch-Schönlein purpura: a systematic review.


]]></description>
			<content:encoded><![CDATA[Related Articles:

Thrombotic microangiopathy and renal failure exacerbated by epsilon-aminocaproic acid.
Association between high ultrafiltration rates and mortality in uraemic patients on regular haemodialysis. A 5-year prospective observational multicentre study.
Prevention and treatment of renal disease in Henoch-Schönlein purpura: a systematic review.


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/interventions-for-haemolytic-uraemic-syndrome-and-thrombotic-thrombocytopenic-purpura/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Thrombotic microangiopathy and renal failure exacerbated by epsilon-aminocaproic acid.</title>
		<link>http://www.nephrologynow.com/publications/thrombotic-microangiopathy-and-renal-failure-exacerbated-by-epsilon-aminocaproic-acid</link>
		<comments>http://www.nephrologynow.com/publications/thrombotic-microangiopathy-and-renal-failure-exacerbated-by-epsilon-aminocaproic-acid#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[General Nephrology]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/thrombotic-microangiopathy-and-renal-failure-exacerbated-by-epsilon-aminocaproic-acid</guid>
		<description><![CDATA[Related Articles:

Alleviation of Sleep Apnea in Patients with Chronic Renal Failure by Nocturnal Cycler–Assisted Peritoneal Dialysis Compared with Conventional Continuous Ambulatory Peritoneal Dialysis.
Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura .
Continuous renal replacement therapy is associated with less chronic renal failure than intermittent haemodialysis after acute renal failure.


]]></description>
			<content:encoded><![CDATA[Related Articles:

Alleviation of Sleep Apnea in Patients with Chronic Renal Failure by Nocturnal Cycler–Assisted Peritoneal Dialysis Compared with Conventional Continuous Ambulatory Peritoneal Dialysis.
Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura .
Continuous renal replacement therapy is associated with less chronic renal failure than intermittent haemodialysis after acute renal failure.


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/thrombotic-microangiopathy-and-renal-failure-exacerbated-by-epsilon-aminocaproic-acid/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>American Journal of Kidney Diseases Quiz Page February 2009</title>
		<link>http://www.nephrologynow.com/publications/american-journal-of-kidney-diseases-quiz-page-february-2009</link>
		<comments>http://www.nephrologynow.com/publications/american-journal-of-kidney-diseases-quiz-page-february-2009#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[General Nephrology]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/american-journal-of-kidney-diseases-quiz-page-february-2009</guid>
		<description><![CDATA[Related Articles:

American Journal of Kidney Diseases Quiz Page February 2007
American Journal of Kidney Diseases Quiz Page February 2008
American Journal of Kidney Diseases Quiz Page October 2007


]]></description>
			<content:encoded><![CDATA[Related Articles:

American Journal of Kidney Diseases Quiz Page February 2007
American Journal of Kidney Diseases Quiz Page February 2008
American Journal of Kidney Diseases Quiz Page October 2007


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/american-journal-of-kidney-diseases-quiz-page-february-2009/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Rapid kidney function decline and mortality risk in older adults.</title>
		<link>http://www.nephrologynow.com/publications/rapid-kidney-function-decline-and-mortality-risk-in-older-adults</link>
		<comments>http://www.nephrologynow.com/publications/rapid-kidney-function-decline-and-mortality-risk-in-older-adults#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[General Nephrology]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/rapid-kidney-function-decline-and-mortality-risk-in-older-adults</guid>
		<description><![CDATA[Related Articles:

Renal Function and Risk of Hip and Vertebral Fractures in Older Women.
Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis.
All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan.


]]></description>
			<content:encoded><![CDATA[Related Articles:

Renal Function and Risk of Hip and Vertebral Fractures in Older Women.
Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis.
All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan.


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/rapid-kidney-function-decline-and-mortality-risk-in-older-adults/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
